Literature Review 13/02/2018: Genetic Risk Of Parkinson'S Disease Dementia Due To Apoe4 Or Mapt

Literature review assessing genetic risk of dementia due to <em>APOE4</em> or <em>MAPT </em>in Parkinson's disease, performed on the 13^th February 2018. All studies had to fulfil three<em> a priori </em>inclusion criteria: 1) Case control studies using clinically diagnosed or pathologically confirmed PD and PDD. 2) Time between motor diagnosis and experimental assessment could be defined or estimated. 3) Genotype information supplied, allowing the odds ratio (OR) and confidence intervals (CI) to be calculated that aligned with the genotype categories used in this work. For <em>MAPT</em>, a PubMed search for the term “<em>MAPT Parkinson’s dementia</em>” identified 105 potential matches, of which 9 met the inclusion criteria. For <em>APOE4</em>, a PubMed search for the term “<em>APOE Parkinson’s dementia</em>” identified 188 potential matches, of which 19 met the inclusion criteria. Note, the review includes several publications arising from the CamPaIGN cohort; As we were interested in genetic risk as a function of time from diagnosis, we included each unique study time-point.本综述于2018年2月13日完成，旨在评估帕金森病（Parkinson's disease）患者中因载脂蛋白E4（APOE4）或微管相关蛋白T（MAPT）基因变异引发痴呆的遗传风险。所有纳入研究均需满足三项先验（a priori）纳入标准： 1) 采用临床确诊或病理证实的帕金森病（Parkinson's disease, PD）及帕金森病痴呆（Parkinson's disease dementia, PDD）的病例对照研究； 2) 可明确或估算运动症状确诊至实验评估之间的时间间隔； 3) 提供基因型信息，能够计算出与本研究采用的基因型分类相匹配的比值比（odds ratio, OR）及置信区间（confidence intervals, CI）。 针对微管相关蛋白T（MAPT），以"MAPT Parkinson’s dementia"为检索词在PubMed数据库中进行检索，共获得105条潜在匹配文献，其中9项符合纳入标准；针对载脂蛋白E4（APOE4），以"APOE Parkinson’s dementia"为检索词在PubMed数据库中检索，共获得188条潜在匹配文献，其中19项符合纳入标准。需注意，本综述纳入了多项源自CamPaIGN队列的研究成果；鉴于我们关注遗传风险与确诊后时间的关联关系，因此纳入了每项研究的独特时间节点数据。